Study of Cryoablation and Nirogacestat for Desmoid Tumor
Phase II Study of Cryoablation and Nirogacestat for Desmoid Tumor
Nam Bui
28 participants
Aug 15, 2023
INTERVENTIONAL
Conditions
Summary
The primary purpose of this protocol is Systemic therapy with oral study agent, nirogacestat, followed by a single cryoablation procedure.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Nirogacestat 150 mg by mouth twice-daily continuously for Cycles 1 through 3. Treatment with nirogacestat may continue via this study protocol for up to 24 months (26 cycles of treatment), unless there is progression of disease, intolerance, start of new anticancer therapy, or Subject Study Completion or Termination occurs.
Cryoablation procedure (single session) of one tumor mass between Cycles 3 and 4 of nirogacestat treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05949099